Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300

被引：21

作者：

Lai, Kwong Wah ^{[1
]}

Romero, F. Anthony ^{[2
]}

Tsui, Vickie ^{[2
]}

Beresini, Maureen H. ^{[2
]}

Boenig, Gladys de Leon ^{[2
]}

Bronner, Sarah M. ^{[2
]}

Chen, Kevin ^{[1
]}

Chen, Zhongguo ^{[1
]}

Choo, Edna F. ^{[2
]}

Crawford, Terry D. ^{[2
]}

Cyr, Patrick ^{[2
]}

Kaufman, Susan ^{[2
]}

Li, Yingjie ^{[1
]}

Liao, Jiangpeng ^{[1
]}

Liu, Wenfeng ^{[1
]}

Ly, Justin ^{[2
]}

Murray, Jeremy ^{[2
]}

Shen, Weichao ^{[1
]}

Wai, John ^{[1
]}

Wang, Fei ^{[1
]}

Zhu, Caicai ^{[1
]}

Zhu, Xiaoyu ^{[1
]}

Magnuson, Steven ^{[2
]}

机构：

[1] WuXi AppTec Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China

[2] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2018年 / 28卷 / 01期

关键词：

Bromodomain; CBP inhibitor; Volume of distribution; Half-life; CREB-BINDING-PROTEIN; CBP; COACTIVATOR; ACETYLATION; P300; DOMAIN;

D O I：

10.1016/j.bmcl.2017.11.025

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel, potent, and orally bioavailable inhibitor of the bromodomain of CBP, compound 35 (GNE-207), has been identified through SAR investigations focused on optimizing al bicyclic heteroarene to replace the aniline present in the published GNE-272 series. Compound 35 has excellent CBP potency ( CBP IC50 = 1 nM, MYC EC50 = 18 nM), a selectively index of > 2500-fold against BRD4(1), and exhibits a good pharmacokinetic profile. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：15 / 23

页数：9

共 50 条

[31] Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors
Zhong, Xue
Deng, Huiwen
Long, Min
Yin, Honglu
Zhong, Qiu
Zheng, Shilong
Gong, Tao
He, Ling
Wang, Guangdi
Sun, Qiu
BIOORGANIC CHEMISTRY, 2023, 138
[32] P300 IS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP
LUNDBLAD, JR
KWOK, RPS
LAURANCE, ME
HARTER, ML
GOODMAN, RH
FASEB JOURNAL, 1995, 9 (06): : A1461 - A1461
[33] Chromatin recognition and regulation of the acetyltransferase CBP/p300
Panne, D.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C1586 - C1586
[34] Role of CBP/P300 in nuclear receptor signalling
Chakravarti, D
LaMorte, VJ
Nelson, MC
Nakajima, T
Schulman, IG
Juguilon, H
Montminy, M
Evans, RM
NATURE, 1996, 383 (6595) : 99 - 103
[35] Molecular cloning and expression of Xenopus p300/CBP
Fujii, G
Tsuchiya, R
Itoh, Y
Tashiro, K
Hirohashi, S
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1443 (1-2): : 41 - 54
[36] Physical and functional interaction of SMADs and p300/CBP
Pouponnot, C
Jayaraman, L
Massagué, J
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) : 22865 - 22868
[37] CBP/p300 are bimodal regulators of Wnt signaling
Li, Jiong
Sutter, Chris
Parker, David S.
Blauwkamp, Timothy
Fang, Ming
Cadigan, Ken M.
EMBO JOURNAL, 2007, 26 (09): : 2284 - 2294
[38] CBP/p300 acetyltransferase activity in hematologic malignancies
Dutta, Ritika
Tiu, Bruce
Sakamoto, Kathleen M.
MOLECULAR GENETICS AND METABOLISM, 2016, 119 (1-2) : 37 - 43
[39] Roles of the acetyltransferases CBP/p300 in breast cancer
Muhmud, Iqbal
Tian, Guimei
Liao, Daiqing
CANCER RESEARCH, 2017, 77
[40] Conjunction dysfunction: CBP/p300 in human disease
Giles, RH
Peters, DJM
Breuning, MH
TRENDS IN GENETICS, 1998, 14 (05) : 178 - 183

← 1 2 3 4 5 →